Tarsus to Participate in Upcoming Investor Conferences

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its participation in two upcoming investor conferences in September 2025.

Rhea-AI Summary

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its participation in two upcoming investor conferences in September 2025. Management will present at the Wells Fargo 20th Annual Healthcare Conference on September 3rd at 9:30 a.m. ET and the H.C. Wainwright 27th Annual Global Investment Conference on September 9th at 10:30 a.m. ET.

Investors can access live webcasts of both presentations through the events section of the Tarsus website. Replay recordings will be available within 48 hours and archived for a limited time.

Argus Aug 28 session

+0.59% close to close Open Argus

Details

News Market Reaction – TARS

On Aug 28, the first trading day after this news, TARS closed 0.59% above the previous close.

Data tracked by StockTitan Argus for the Aug 28 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:

• Wells Fargo 20^th Annual Healthcare Conference on Wednesday, September 3^rd, at 6:30 a.m. PT / 9:30 a.m. ET
• H.C. Wainwright 27^th Annual Global Investment Conference on Tuesday, September 9^th, at 7:30 a.m. PT / 10:30 a.m. ET

Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 as an ophthalmic gel for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Tarsus Pharmaceuticals (TARS) presenting at the Wells Fargo Healthcare Conference 2025?

Tarsus will present at the Wells Fargo Healthcare Conference on Wednesday, September 3rd, 2025 at 9:30 a.m. ET.

When is the H.C. Wainwright Conference presentation for Tarsus (TARS)?

Tarsus will present at the H.C. Wainwright Global Investment Conference on Tuesday, September 9th, 2025 at 10:30 a.m. ET.

How can investors access Tarsus (TARS) conference presentations?

Investors can access live webcasts through the events section of the Tarsus website. Replays will be available within 48 hours and archived for a limited time.

Which investor conferences is Tarsus Pharmaceuticals (TARS) attending in September 2025?

Tarsus is attending the Wells Fargo 20th Annual Healthcare Conference on September 3rd and the H.C. Wainwright 27th Annual Global Investment Conference on September 9th.